NeoGenomics Inc (NEO): Cost of Revenue
$413.04M
Year ended 2025-12-31
$429.76M
Trailing 12 months to 2026-06-30
+8.7%
3-year compound annual growth
+9.8%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $413.04M | +11.5% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $370.47M | +6.8% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $347.04M | +7.8% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $321.83M | +8.3% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $297.27M | +15.0% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $258.56M | +22.0% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $211.99M | +41.8% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $149.48M | +8.1% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $138.29M | +3.4% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $133.70M | n/a | 2019-02-26, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| NeoGenomics Inc (NEO) | 2025-12-31 | $413.04M | +11.5% |
| UL Solutions Inc. (ULS) | 2025-12-31 | $1.54B | +4.4% |
| Incyte Corp (INCY) | 2025-12-31 | $372.13M | +19.2% |
| Icon PLC (ICLR) | 2024-12-31 | $5.85B | +2.2% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $6.22M | -12.4% |
| 20/20 Biolabs, Inc. (AIDX) | 2025-12-31 | $1.44M | +3.5% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.90M | -64.1% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $1.86M | +101.5% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $40.1K | -12.0% |
Compare NEO, ULS, INCY, ICLR side by side · Screen every company in Services-Testing Laboratories ↗